Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024

December 13, 2023

https://www.globenewswire.com/news-release/2023/12/12/2795108/0/en/Caribou-Biosciences-Provides-Regulatory-Update-on-CB-010-Pivotal-Plan-with-Phase-3-Trial-Initiation-Expected-by-YE-2024.html

— Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT —

Read more at globenewswire.com

Related news for (CRBU)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.